secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2025-12-10T23:59:59+00:00
Accession:  0001824293-25-000167
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio announces positive Phase 2a topline results for GRI-0621 in IPF
-----------------------------------------------------------------------

- Primary endpoint met: GRI-0621 well tolerated with no drug-related severe/serious adverse events; no GI increase vs placebo.
- Biomarkers improved: type VI collagen remodeling shifted from fibrogenic (+10%) to fibrolytic (-7%), suggesting fibrosis resolution.
- FVC improved: placebo-adjusted increase of 99ml (139ml with standard of care); 39% of GRI-0621 subjects gained FVC vs 80% of placebo declined.
- Type IV collagen remodeling shifted to neutral (0%) vs fibrolytic (-16%) in placebo, indicating alveolar basement membrane repair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429325000167/0001824293-25-000167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429325000167/val-20251210.htm
  HTML page:      https://secwatch.observer/filing/0001824293-25-000167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer